Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?

Clostridioides difficile infection (CDI) is a pressing health care issue due to the limited effectiveness of current treatments and high recurrence rates. Current available antibiotic options for CDI disrupt the fecal microbiome which predisposes recurrent CDI. Fecal microbiota transplantation (FMT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagarakanti, Sandhya, Orenstein, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208241/
https://www.ncbi.nlm.nih.gov/pubmed/37235073
http://dx.doi.org/10.2147/IDR.S400570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208241/
https://www.ncbi.nlm.nih.gov/pubmed/37235073
http://dx.doi.org/10.2147/IDR.S400570

Ejemplares similares